Alveolar OsteitisNCT07790653
Alvogyl Versus Platelet-Rich Fibrin for Healing of Alveolar Osteitis
A study testing Alvogyl Dressing and Platelet-Rich Fibrin (PRF) in people with Alveolar Osteitis, run by CMH Lahore Medical College and Institute of Dentistry at 1 site in Pakistan.
Trial summary
Alveolar osteitis, commonly known as dry socket, is a painful complication that can occur after tooth extraction, particularly following removal of a mandibular third molar. It occurs when normal healing of the extraction socket is disrupted and is commonly associated with significant pain and delayed healing. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Alveolar Osteitis
- What is being tested?
- Alvogyl Dressing and Platelet-Rich Fibrin (PRF)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 102 participants
- Where
- 1 sitePakistan
- Study dates
- 10 Feb 2026to 15 Oct 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older.
- Participants of either sex.
- Patients presenting with alveolar osteitis following third molar extraction, diagnosed according to the study's operational definition.
- Patients willing to participate in the study and provide informed consent.
- Patients willing and able to attend the scheduled postoperative follow-up assessments.
Who cannot join
- Patients with a smoking habit.
- Patients with a history of bleeding disorders.
- Patients unwilling or unable to attend the required follow-up sessions.
- Patients with a history of hypertension, diabetes mellitus, liver disease, or renal disease.
- Pregnant or breastfeeding individuals.
- Patients using medications that may affect healing or study outcomes, including bisphosphonates, systemic steroids, or antidepressants.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Comparative Study of the Healing Status by the Use of Alvogyl and Platelet-Rich Fibrin in the Treatment of Alveolar Osteitis: A Randomized Double-Blind Controlled Clinical Trial
Alveolar osteitis, commonly known as dry socket, is a painful complication that can occur after tooth extraction, particularly following removal of a mandibular third molar. It occurs when normal healing of the extraction socket is disrupted and is commonly associated with significant pain and delayed healing. Alvogyl is a commonly used dressing for managing dry socket and can provide rapid pain relief. Platelet-rich fibrin (PRF) is a preparation made from the patient's own blood that contains platelets, white blood cells, fibrin, and growth factors that may promote tissue repair and wound healing.
This randomized controlled clinical trial will compare Alvogyl and platelet-rich fibrin in patients diagnosed with alveolar osteitis following third molar extraction. A total of 102 eligible adult participants will be randomly assigned to receive either Alvogyl or PRF as treatment for the affected extraction socket.
Read more
The study will compare the healing outcomes of the two treatments by assessing pain intensity and the number of exposed socket walls during follow-up. Pain will be assessed using a visual analogue scale, while socket healing will be evaluated clinically by recording the number of exposed socket walls.
The study aims to determine whether PRF provides better healing outcomes than conventional Alvogyl treatment for alveolar osteitis. The findings may help clinicians select an effective treatment approach for reducing pain and promoting healing in patients with dry socket.
Read the detailed description
Alveolar osteitis, commonly referred to as dry socket, is a frequent painful complication following tooth extraction. It is characterized by persistent or increasing postoperative pain, typically developing within the first few days after extraction, and may be associated with an empty extraction socket, foul odour, and delayed local healing. The condition can substantially affect patient comfort and quality of life and may require additional clinical management.
Several treatment approaches have been used for alveolar osteitis, including socket irrigation, local dressings, analgesics, antibiotics in selected circumstances, and regenerative materials. Alvogyl is a commonly used intra-alveolar dressing that is intended to provide symptomatic relief and protect the affected socket. Although it can provide rapid pain relief, concerns have been raised regarding its potential effect on the rate of socket healing.
Platelet-rich fibrin (PRF) is an autologous platelet concentrate prepared from the patient's own venous blood without the use of anticoagulants. During centrifugation, a fibrin-rich matrix containing platelets and leukocytes is formed. This matrix serves as a scaffold for tissue repair and provides a sustained release of biologically active mediators, including growth factors involved in angiogenesis, cellular proliferation, and wound healing. PRF has therefore been investigated as a regenerative treatment for extraction socket healing and alveolar osteitis.
Previous clinical studies comparing Alvogyl and PRF have reported differences in pain relief and socket healing. Some evidence suggests that Alvogyl may provide more rapid symptomatic pain relief, whereas PRF may promote more favourable or faster clinical healing. However, variation in study findings and treatment protocols indicates a need for further controlled clinical investigation.
This study is designed as a randomized, double-blind, controlled clinical trial comparing Alvogyl with PRF for the treatment of alveolar osteitis following third molar extraction. Eligible participants will be randomly allocated to receive either Alvogyl or an autologous PRF membrane. Both treatment groups will undergo standardized socket irrigation and debridement before placement of the assigned treatment. The extraction socket will subsequently be secured using sutures.
The primary purpose of the study is to compare healing outcomes between the two treatment approaches. Clinical assessment will include evaluation of pain intensity using a 0-10 visual analogue scale and assessment of the number of exposed socket walls. Participants will be assessed during postoperative follow-up to determine changes in pain and socket healing.
A total of 102 adult participants will be enrolled, with 51 participants allocated to each treatment group. The study will be conducted in the Department of Oral and Maxillofacial Surgery at CMH Medical College and Institute of Dentistry, Lahore. All procedures will be performed by the same surgical team under the supervision of an experienced consultant oral surgeon.
The study will provide comparative clinical evidence regarding the use of conventional Alvogyl dressing and autologous PRF for management of alveolar osteitis. The findings may contribute to evidence-based selection of treatment modalities aimed at reducing postoperative pain and improving healing of affected extraction sockets.
- Conditions
- Alveolar Osteitis
- Being tested
- Alvogyl Dressing, Platelet-Rich Fibrin (PRF)
- Keywords
- Alveolar Osteitis, Dry socket, Platelet-rich fibrin, Extraction socket, Third molar extraction
- Medical subject headings
- Dry Socket
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Alvogyl DressingProcedure or surgery
Alvogyl will be used as an intra-alveolar dressing for the treatment of alveolar osteitis. Following gentle irrigation of the extraction socket with warm saline and debridement, Alvogyl will be placed into the socket. The socket will then be secured with 3-0 silk sutures using a figure-of-eight technique to maintain the dressing in position. No topical or systemic antibiotics will be administered.
Platelet-Rich Fibrin (PRF)Biological
Autologous platelet-rich fibrin will be prepared from 10 mL of the participant's venous blood collected into two 5-mL tubes without anticoagulant. The blood will be centrifuged at 3000 rpm for 10 minutes. The resulting PRF layer will be separated and compressed between sterile saline-moistened gauze to form a membrane. Following standard socket irrigation and debridement with warm saline, the PRF membrane will be placed into the extraction socket and secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered.
| Study group | Role | What they receive |
|---|---|---|
| Alvogyl Group | Active comparator | Participants diagnosed with alveolar osteitis will receive standard socket irrigation with warm saline and debridement, followed by placement of Alvogyl into the extraction socket. The socket will be secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered. Receives: Procedure: Alvogyl Dressing |
| Platelet-Rich Fibrin Group | Experimental | Participants diagnosed with alveolar osteitis will receive autologous platelet-rich fibrin (PRF). Ten millilitres of venous blood will be collected and centrifuged without anticoagulant to prepare a PRF membrane. Following standard socket irrigation and debridement with warm saline, the PRF membrane will be placed into the extraction socket and secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered. Receives: Biological: Platelet-Rich Fibrin (PRF) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Pain Score
Pain intensity will be assessed using a 0-10 Visual Analogue Scale (VAS), where 0 indicates no pain and 10 indicates the worst possible pain. The mean VAS pain score on postoperative Days 1 and 3 will be compared between the Alvogyl and platelet-rich fibrin groups.
Measured: Postoperative Day 1 and 3
Mean Number of Socket Wall Exposures
The number of exposed socket walls will be assessed by clinical examination on postoperative Days 1 and 3. The mean number of socket wall exposures will be compared between the Alvogyl and platelet-rich fibrin groups to evaluate the healing status of the extraction socket.
Measured: Days 1 and 3
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2026
- Study start10 Feb 2026
- Primary completion25 Sep 2026
- Study completion15 Oct 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alveolar OsteitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 102 participants (actual)
Sponsor and investigators
- Lead sponsor
- CMH Lahore Medical College and Institute of Dentistry
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Asad A Chatha, BDS, FCPS, Study chair, CMH Lahore Medical College and Institute of Dentistry
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07790653
- Sponsor's protocol ID
- 219/ERC/CMH/LMC
- Status last verified
- Oct 2026
- First submitted
- 24 Aug 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparative Study of the Healing Status by the Use of Alvogyl and Platelet-Rich Fibrin in the Treatment of Alveolar Osteitis: A Randomized Double-Blind Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT07790653
- Acronym / sponsor ID
- 219/ERC/CMH/LMC
- Conditions
- Alveolar Osteitis
- Keywords
- Alveolar Osteitis, Dry socket, Platelet-rich fibrin, Extraction socket, Third molar extraction
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 102 participants (actual)
- Lead sponsor
- CMH Lahore Medical College and Institute of DentistryUniversity, hospital or other
- Study start
- 10 Feb 2026 (actual)
- Primary completion
- 25 Sep 2026 (actual)
- Study completion
- 15 Oct 2026 (actual)
- First posted
- 27 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Alveolar osteitis, commonly known as dry socket, is a painful complication that can occur after tooth extraction, particularly following removal of a mandibular third molar. It occurs when normal healing of the extraction socket is disrupted and is commonly associated with significant pain and delayed healing. Alvogyl is a commonly used dressing for managing dry socket and can provide rapid pain relief. Platelet-rich fibrin (PRF) is a preparation made from the patient's own blood that contains platelets, white blood cells, fibrin, and growth factors that may promote tissue repair and wound healing.
This randomized controlled clinical trial will compare Alvogyl and platelet-rich fibrin in patients diagnosed with alveolar osteitis following third molar extraction. A total of 102 eligible adult participants will be randomly assigned to receive either Alvogyl or PRF as treatment for the affected extraction socket.
The study will compare the healing outcomes of the two treatments by assessing pain intensity and the number of exposed socket walls during follow-up. Pain will be assessed using a visual analogue scale, while socket healing will be evaluated clinically by recording the number of exposed socket walls.
The study aims to determine whether PRF provides better healing outcomes than conventional Alvogyl treatment for alveolar osteitis. The findings may help clinicians select an effective treatment approach for reducing pain and promoting healing in patients with dry socket.
Detailed description
Alveolar osteitis, commonly referred to as dry socket, is a frequent painful complication following tooth extraction. It is characterized by persistent or increasing postoperative pain, typically developing within the first few days after extraction, and may be associated with an empty extraction socket, foul odour, and delayed local healing. The condition can substantially affect patient comfort and quality of life and may require additional clinical management.
Several treatment approaches have been used for alveolar osteitis, including socket irrigation, local dressings, analgesics, antibiotics in selected circumstances, and regenerative materials. Alvogyl is a commonly used intra-alveolar dressing that is intended to provide symptomatic relief and protect the affected socket. Although it can provide rapid pain relief, concerns have been raised regarding its potential effect on the rate of socket healing.
Platelet-rich fibrin (PRF) is an autologous platelet concentrate prepared from the patient's own venous blood without the use of anticoagulants. During centrifugation, a fibrin-rich matrix containing platelets and leukocytes is formed. This matrix serves as a scaffold for tissue repair and provides a sustained release of biologically active mediators, including growth factors involved in angiogenesis, cellular proliferation, and wound healing. PRF has therefore been investigated as a regenerative treatment for extraction socket healing and alveolar osteitis.
Previous clinical studies comparing Alvogyl and PRF have reported differences in pain relief and socket healing. Some evidence suggests that Alvogyl may provide more rapid symptomatic pain relief, whereas PRF may promote more favourable or faster clinical healing. However, variation in study findings and treatment protocols indicates a need for further controlled clinical investigation.
This study is designed as a randomized, double-blind, controlled clinical trial comparing Alvogyl with PRF for the treatment of alveolar osteitis following third molar extraction. Eligible participants will be randomly allocated to receive either Alvogyl or an autologous PRF membrane. Both treatment groups will undergo standardized socket irrigation and debridement before placement of the assigned treatment. The extraction socket will subsequently be secured using sutures.
The primary purpose of the study is to compare healing outcomes between the two treatment approaches. Clinical assessment will include evaluation of pain intensity using a 0-10 visual analogue scale and assessment of the number of exposed socket walls. Participants will be assessed during postoperative follow-up to determine changes in pain and socket healing.
A total of 102 adult participants will be enrolled, with 51 participants allocated to each treatment group. The study will be conducted in the Department of Oral and Maxillofacial Surgery at CMH Medical College and Institute of Dentistry, Lahore. All procedures will be performed by the same surgical team under the supervision of an experienced consultant oral surgeon.
The study will provide comparative clinical evidence regarding the use of conventional Alvogyl dressing and autologous PRF for management of alveolar osteitis. The findings may contribute to evidence-based selection of treatment modalities aimed at reducing postoperative pain and improving healing of affected extraction sockets.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Alvogyl Group | Active comparator | Procedure: Alvogyl DressingParticipants diagnosed with alveolar osteitis will receive standard socket irrigation with warm saline and debridement, followed by placement of Alvogyl into the extraction socket. The socket will be secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered. |
| Platelet-Rich Fibrin Group | Experimental | Biological: Platelet-Rich Fibrin (PRF)Participants diagnosed with alveolar osteitis will receive autologous platelet-rich fibrin (PRF). Ten millilitres of venous blood will be collected and centrifuged without anticoagulant to prepare a PRF membrane. Following standard socket irrigation and debridement with warm saline, the PRF membrane will be placed into the extraction socket and secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults aged 18 years or older.
- Participants of either sex.
- Patients presenting with alveolar osteitis following third molar extraction, diagnosed according to the study's operational definition.
- Patients willing to participate in the study and provide informed consent.
- Patients willing and able to attend the scheduled postoperative follow-up assessments.
Key exclusion criteria (6 listed)
- Patients with a smoking habit.
- Patients with a history of bleeding disorders.
- Patients unwilling or unable to attend the required follow-up sessions.
- Patients with a history of hypertension, diabetes mellitus, liver disease, or renal disease.
- Pregnant or breastfeeding individuals.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Alvogyl DressingAlvogyl will be used as an intra-alveolar dressing for the treatment of alveolar osteitis. Following gentle irrigation of the extraction socket with warm saline and debridement, Alvogyl will be placed into the socket. The socket will then be secured with 3-0 silk sutures using a figure-of-eight technique to maintain the dressing in position. No topical or systemic antibiotics will be administered. | Procedure or surgery | Alvogyl Group |
| Platelet-Rich Fibrin (PRF)Autologous platelet-rich fibrin will be prepared from 10 mL of the participant's venous blood collected into two 5-mL tubes without anticoagulant. The blood will be centrifuged at 3000 rpm for 10 minutes. The resulting PRF layer will be separated and compressed between sterile saline-moistened gauze to form a membrane. Following standard socket irrigation and debridement with warm saline, the PRF membrane will be placed into the extraction socket and secured with 3-0 silk sutures using a figure-of-eight technique. No topical or systemic antibiotics will be administered. | Biological | Platelet-Rich Fibrin Group |
Primary outcome
Mean Pain Score
Time frame: Postoperative Day 1 and 3
Pain intensity will be assessed using a 0-10 Visual Analogue Scale (VAS), where 0 indicates no pain and 10 indicates the worst possible pain. The mean VAS pain score on postoperative Days 1 and 3 will be compared between the Alvogyl and platelet-rich fibrin groups.
Mean Number of Socket Wall Exposures
Time frame: Days 1 and 3
The number of exposed socket walls will be assessed by clinical examination on postoperative Days 1 and 3. The mean number of socket wall exposures will be compared between the Alvogyl and platelet-rich fibrin groups to evaluate the healing status of the extraction socket.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Alveolar Osteitis
Recruiting
Effect of Curcumin Topical Spray on Wound Healing After Tooth Extraction
Wound Healing, Alveolitis of Jaw
Not yet recruiting
Comparative Efficacy of Amoxicillin, Metronidazole, and Chlorhexidine in Preventing Alveolar Osteitis
Alveolar Osteitis
Not yet recruiting
Effectiveness of Telephonic and Digital Postoperative Follow-up Communication Strategies on Patient Compliance, Clinical Recovery, and Quality of Life After Dental Extraction
Tooth Extraction, Postoperative Care
RecruitingObservational study
PERIodontal Disease, Microbiota and Miscarriage
Miscarriage, Parodontitis
Active, not recruitingEarly Phase 1
Ozone Oil-based Gel and CHX Gel After Lower Third Molar Removal
Pain, Dry Socket
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Asad A Chatha, BDS, FCPS study chair
CMH Lahore Medical College and Institute of Dentistry
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Alvogyl Dressing and Platelet-Rich Fibrin (PRF) in people with Alveolar Osteitis, run by CMH Lahore Medical College and Institute of Dentistry at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Pain Score (time frame: Postoperative Day 1 and 3). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.